Identification

Name
Clocortolone
Accession Number
DB00838  (APRD00877)
Type
Small Molecule
Groups
Approved
Description

Clocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp.

Structure
Thumb
Synonyms
  • 9-chloro-6alpha-Fluoro-11beta,21-dihydroxy-16alpha-methyl-1,4-pregnadien-3,20-dione
  • 9-chloro-6alpha-Fluoro-16alpha-methyl-1,4-pregnadiene-11beta,21-diol-3,20-dione
  • Clocortolon
  • Clocortolona
  • Clocortolone
  • Clocortolonum
External IDs
SH 863
Product Ingredients
IngredientUNIICASInChI Key
Clocortolone acetate85061HTR8T4258-85-9ARPLCFGLEYFDCN-CDACMRRYSA-N
Clocortolone caproate871M9PSU7T4891-71-8MMTRTBFDFNRBQO-ANHDKODLSA-N
Clocortolone pivalateQBL8IZH14X34097-16-0SXYZQZLHAIHKKY-GSTUPEFVSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clocortolone PivalateCream.001 g/gTopicalDr Reddy's Laboratories2014-02-17Not applicableUs
ClodermCream.001 g/gTopicalCoria Laboratories1977-08-222016-05-01Us
ClodermCream.001 g/gTopicalPromius Pharma, LLC1977-08-22Not applicableUs
Categories
UNII
N8ZUB7XE0H
CAS number
4828-27-7
Weight
Average: 410.907
Monoisotopic: 410.166015296
Chemical Formula
C22H28ClFO4
InChI Key
YMTMADLUXIRMGX-RFPWEZLHSA-N
InChI
InChI=1S/C22H28ClFO4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-21(15,3)22(14,23)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1
IUPAC Name
(1R,2S,8S,10S,11S,13R,14S,15S,17S)-1-chloro-8-fluoro-17-hydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES

Pharmacology

Indication

For short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.

Structured Indications
Pharmacodynamics

Like other topical corticosteroids, clocortolone has anti-inflammatory, antipruritic, and vasoconstrictive properties. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Clocortolone is a moderate potency topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved.

Mechanism of action

The precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. These enzyme transcriptional changes are mediated by the drug binding first to the glucocorticoid receptor. This complex can migrate to the cell nucleus which then binds to DNA initiating genetic activation and repression of various genes.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Metabolized, primarily in the liver, and then excreted by the kidneys.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Topically applied clocortolone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Clocortolone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Clocortolone.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Clocortolone.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Clocortolone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Clocortolone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Clocortolone.Approved, Withdrawn
AldesleukinClocortolone may decrease the antineoplastic activities of Aldesleukin.Approved
AlgeldrateThe bioavailability of Clocortolone can be decreased when combined with Algeldrate.Experimental
AlmagateThe bioavailability of Clocortolone can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Clocortolone can be decreased when combined with Almasilate.Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Clocortolone.Experimental
AloglutamolThe bioavailability of Clocortolone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Clocortolone.Experimental
AluminiumThe bioavailability of Clocortolone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Clocortolone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Clocortolone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Clocortolone can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Clocortolone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Clocortolone.Approved
AmiodaroneThe serum concentration of Clocortolone can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BClocortolone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Clocortolone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Clocortolone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Clocortolone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Clocortolone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Clocortolone.Approved, Investigational
AprepitantThe serum concentration of Clocortolone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Clocortolone can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Clocortolone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clocortolone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Clocortolone.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Clocortolone.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Clocortolone is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Clocortolone.Experimental
BendroflumethiazideClocortolone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Clocortolone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Clocortolone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Clocortolone.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Clocortolone.Experimental
Bismuth SubcitrateThe bioavailability of Clocortolone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Clocortolone can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Clocortolone can be increased when it is combined with Boceprevir.Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clocortolone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Clocortolone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Clocortolone.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Clocortolone.Experimental
BumetanideClocortolone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Clocortolone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Clocortolone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Clocortolone can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideClocortolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Clocortolone can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Clocortolone.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Clocortolone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clocortolone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clocortolone.Approved, Investigational
CeritinibClocortolone may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Clocortolone.Approved, Vet Approved
ChlorothiazideClocortolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Clocortolone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneClocortolone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Clocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Clocortolone.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Cinoxacin.Approved, Withdrawn
ClarithromycinThe serum concentration of Clocortolone can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Clocortolone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Clocortolone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Clocortolone can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Clocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Clocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Clocortolone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Clocortolone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Clocortolone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Clocortolone is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Clocortolone.Investigational
CyclopenthiazideClocortolone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Clocortolone.Investigational
DaidzeinThe serum concentration of Clocortolone can be increased when it is combined with Daidzein.Experimental
DarunavirThe serum concentration of Clocortolone can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Clocortolone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Clocortolone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Clocortolone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Clocortolone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Clocortolone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Clocortolone.Approved, Vet Approved
DienestrolThe serum concentration of Clocortolone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Clocortolone can be increased when it is combined with Diethylstilbestrol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Clocortolone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clocortolone.Approved
DihydrotestosteroneClocortolone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Clocortolone is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Clocortolone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Clocortolone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Clocortolone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Clocortolone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Clocortolone is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Clocortolone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Clocortolone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Clocortolone.Approved
EquolThe serum concentration of Clocortolone can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Clocortolone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Clocortolone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Clocortolone can be increased when it is combined with Estrone.Approved
Etacrynic acidClocortolone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Clocortolone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Clocortolone.Experimental
Ethinyl EstradiolThe serum concentration of Clocortolone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Clocortolone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Clocortolone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clocortolone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Clocortolone.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Clocortolone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Clocortolone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Clocortolone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Clocortolone.Approved
FenthionThe risk or severity of adverse effects can be increased when Clocortolone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Clocortolone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Clocortolone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Clocortolone.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Clocortolone.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Clocortolone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Clocortolone.Experimental
FluoxymesteroneClocortolone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Clocortolone.Approved, Investigational
FosaprepitantThe serum concentration of Clocortolone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Clocortolone can be decreased when it is combined with Fosphenytoin.Approved
FurosemideClocortolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Clocortolone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Clocortolone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Clocortolone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Clocortolone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Clocortolone is combined with Ginkgo biloba.Approved, Nutraceutical
GLPG-0492Clocortolone may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Clocortolone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Clocortolone.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Clocortolone.Experimental
HexestrolThe serum concentration of Clocortolone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Clocortolone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Clocortolone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clocortolone.Approved, Investigational
HydrochlorothiazideClocortolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideClocortolone may increase the hypokalemic activities of Hydroflumethiazide.Approved
HydrotalciteThe bioavailability of Clocortolone can be decreased when combined with Hydrotalcite.Experimental
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Clocortolone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Clocortolone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Clocortolone.Approved
IdelalisibThe serum concentration of Clocortolone can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Clocortolone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Clocortolone.Approved
IndapamideClocortolone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Clocortolone can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Clocortolone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clocortolone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Clocortolone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Clocortolone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Clocortolone is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Clocortolone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Clocortolone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Clocortolone.Withdrawn
ItraconazoleThe serum concentration of Clocortolone can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Clocortolone.Experimental
KetoconazoleThe serum concentration of Clocortolone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Clocortolone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Clocortolone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Clocortolone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Clocortolone.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Clocortolone.Experimental
LopinavirThe serum concentration of Clocortolone can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clocortolone.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Clocortolone.Approved
LumacaftorThe serum concentration of Clocortolone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Clocortolone.Approved, Investigational
MagaldrateThe bioavailability of Clocortolone can be decreased when combined with Magaldrate.Withdrawn
Magnesium HydroxideThe bioavailability of Clocortolone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Clocortolone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Clocortolone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clocortolone.Approved
Magnesium silicateThe bioavailability of Clocortolone can be decreased when combined with Magnesium silicate.Experimental
Magnesium TrisilicateThe bioavailability of Clocortolone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Clocortolone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clocortolone.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clocortolone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Clocortolone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Clocortolone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Clocortolone.Approved
MesteroloneClocortolone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Clocortolone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Clocortolone.Withdrawn
MethallenestrilThe serum concentration of Clocortolone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Clocortolone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideClocortolone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Clocortolone is combined with Methyl salicylate.Approved, Vet Approved
MethyltestosteroneClocortolone may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Clocortolone is combined with Metoclopramide.Approved, Investigational
MetolazoneClocortolone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Clocortolone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Minaprine.Approved
MitotaneThe serum concentration of Clocortolone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Clocortolone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clocortolone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Clocortolone.Experimental
MoxestrolThe serum concentration of Clocortolone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clocortolone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clocortolone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Clocortolone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Clocortolone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Clocortolone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Clocortolone is combined with Nalidixic Acid.Approved
NandroloneClocortolone may increase the fluid retaining activities of Nandrolone.Experimental
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Clocortolone.Approved, Vet Approved
NefazodoneThe serum concentration of Clocortolone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Clocortolone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Clocortolone.Approved
NevirapineThe serum concentration of Clocortolone can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Clocortolone is combined with Nicorandil.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Clocortolone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clocortolone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clocortolone.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Clocortolone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clocortolone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Clocortolone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Clocortolone.Vet Approved
OxandroloneClocortolone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clocortolone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Clocortolone is combined with Oxolinic acid.Experimental
OxymetholoneClocortolone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clocortolone.Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Clocortolone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Clocortolone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Clocortolone.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Clocortolone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Clocortolone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Clocortolone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clocortolone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Clocortolone.Approved, Investigational
PhenytoinThe serum concentration of Clocortolone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clocortolone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Clocortolone is combined with Pipemidic acid.Experimental
PiretanideClocortolone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clocortolone.Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Clocortolone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clocortolone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Clocortolone.Experimental
Polyestradiol phosphateThe serum concentration of Clocortolone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideClocortolone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Clocortolone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Clocortolone.Experimental
PrimidoneThe serum concentration of Clocortolone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Clocortolone.Experimental
PromestrieneThe serum concentration of Clocortolone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Clocortolone.Approved
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Clocortolone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Clocortolone.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Clocortolone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Clocortolone can be increased when it is combined with Quinestrol.Approved
QuinethazoneClocortolone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Clocortolone is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Clocortolone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clocortolone.Experimental, Investigational
RifabutinThe serum concentration of Clocortolone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Clocortolone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Clocortolone can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Clocortolone is combined with Rindopepimut.Investigational
RitonavirThe serum concentration of Clocortolone can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Clocortolone.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Rosoxacin.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clocortolone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clocortolone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Clocortolone.Approved
SaquinavirThe serum concentration of Clocortolone can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Clocortolone can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Clocortolone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Clocortolone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Clocortolone.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Sitafloxacin.Experimental
SparfloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Clocortolone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Clocortolone.Investigational
St. John's WortThe serum concentration of Clocortolone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololClocortolone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Clocortolone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clocortolone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Clocortolone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Clocortolone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Clocortolone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Clocortolone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Clocortolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Tacrine.Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Clocortolone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Clocortolone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Clocortolone.Withdrawn
TelithromycinThe serum concentration of Clocortolone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Clocortolone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Clocortolone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Clocortolone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Clocortolone.Approved
TestosteroneClocortolone may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Clocortolone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clocortolone.Approved
TiboloneThe serum concentration of Clocortolone can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Clocortolone.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clocortolone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clocortolone.Approved
TorasemideClocortolone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Clocortolone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Clocortolone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Clocortolone is combined with Trichlorfon.Vet Approved
TrichlormethiazideClocortolone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Clocortolone.Investigational
TrovafloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Clocortolone.Investigational, Withdrawn
VoriconazoleThe serum concentration of Clocortolone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinClocortolone may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clocortolone.Approved
ZeranolThe serum concentration of Clocortolone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Clocortolone.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clocortolone.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Zoster vaccine.Approved
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
Human Metabolome Database
HMDB14976
KEGG Drug
D07719
PubChem Compound
5311052
PubChem Substance
46505290
ChemSpider
4470589
ChEBI
59582
Therapeutic Targets Database
DAP001190
PharmGKB
PA164744013
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Clocortolone
ATC Codes
D07AB21 — Clocortolone
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Download (167 KB)
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentPsoriasis1

Pharmacoeconomics

Manufacturers
  • Dow pharmaceutical sciences inc
Packagers
Dosage forms
FormRouteStrength
CreamTopical.001 g/g
Prices
Unit descriptionCostUnit
Cloderm 0.1% Cream 45 gm Tube140.98USD tube
Cloderm 0.1% cream3.64USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP3.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.015 mg/mLALOGPS
logP2.73ALOGPS
logP2.47ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)13.53ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity105.74 m3·mol-1ChemAxon
Polarizability41.8 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9737
Caco-2 permeable+0.8054
P-glycoprotein substrateSubstrate0.7404
P-glycoprotein inhibitor INon-inhibitor0.7095
P-glycoprotein inhibitor IINon-inhibitor0.8814
Renal organic cation transporterNon-inhibitor0.8141
CYP450 2C9 substrateNon-substrate0.8412
CYP450 2D6 substrateNon-substrate0.8977
CYP450 3A4 substrateSubstrate0.7374
CYP450 1A2 substrateNon-inhibitor0.9164
CYP450 2C9 inhibitorNon-inhibitor0.9119
CYP450 2D6 inhibitorNon-inhibitor0.9061
CYP450 2C19 inhibitorNon-inhibitor0.9182
CYP450 3A4 inhibitorInhibitor0.6251
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.857
Ames testNon AMES toxic0.8537
CarcinogenicityNon-carcinogens0.8855
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9732 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9619
hERG inhibition (predictor II)Non-inhibitor0.5411
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Alpha-hydroxy ketones / Secondary alcohols / Chlorohydrins / Cyclic ketones
show 8 more
Substituents
21-hydroxysteroid / Progestogin-skeleton / 20-oxosteroid / Pregnane-skeleton / 6-halo-steroid / Halo-steroid / 3-oxo-delta-1,4-steroid / 9-halo-steroid / 3-oxosteroid / Oxosteroid
show 24 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, glucocorticoid, 20-oxo steroid, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, chlorinated steroid, 21-hydroxy steroid (CHEBI:59582)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Ali A, Balkovec JM, Greenlee M, Hammond ML, Rouen G, Taylor G, Einstein M, Ge L, Harris G, Kelly TM, Mazur P, Pandit S, Santoro J, Sitlani A, Wang C, Williamson J, Forrest MJ, Carballo-Jane E, Luell S, Lowitz K, Visco D: Discovery of betamethasone 17alpha-carbamates as dissociated glucocorticoid receptor modulators in the rat. Bioorg Med Chem. 2008 Aug 15;16(16):7535-42. doi: 10.1016/j.bmc.2008.07.037. Epub 2008 Jul 20. [PubMed:18691892]
  2. Buchwald P: Glucocorticoid receptor binding: a biphasic dependence on molecular size as revealed by the bilinear LinBiExp model. Steroids. 2008 Feb;73(2):193-208. Epub 2007 Oct 11. [PubMed:18022656]
  3. Tanigawa K, Nagase H, Ohmori K, Tanaka K, Miyake H, Kiniwa M, Ikizawa K: Species-specific differences in the glucocorticoid receptor transactivation function upon binding with betamethasone-esters. Int Immunopharmacol. 2002 Jun;2(7):941-50. [PubMed:12188035]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:46